Agoracom Blog Home

Posts Tagged ‘small cap’

Hilaria Baldwin Joins Else Nutrition $BABY.ca as a Brand Ambassador for Plant-Based Toddler Nutrition Launch in U.S. $KMB $BMY $ABT $WYE

Posted by AGORACOM-JC at 7:16 AM on Wednesday, September 9th, 2020
http://blog.agoracom.com/wp-content/uploads/2020/03/else-square-150x150.png
  • Announced partnership with celebrity author, podcast host and parenting expert, Hilaria Baldwin
  • Baldwin has joined Else Nutrition as part of its U.S. launch marketing efforts around its Complete Toddler Nutrition

VANCOUVER, BC / September 9, 2020 / Else Nutrition Holdings (TSXV:BABY)(OTCQX:BABYF)(FSE:0YL) (“Else” or the “Company”), is pleased to announce its partnership with celebrity author, podcast host and parenting expert, Hilaria Baldwin. Baldwin has joined Else Nutrition as part of its U.S. launch marketing efforts around its Complete Toddler Nutrition.

As a mom who has always advocated a plant-based lifestyle, the collaboration originated from Hilaria’s own search for a suitable toddler formula alternative for her children. Baldwin will help Else through creative social media and video content that highlights her findings and journey as a plant-based mother.

“Hilaria embodies our brand values through her desire to take baby nutrition to the next level with a heightened awareness for health and wellness,” said Mrs. Hamutal Yitzhak, CEO and Co-Founder of Else. “She is a true champion of the cause, which makes us beyond excited about this collaboration. Together, we hope to raise awareness of the benefits of clean-label, plant-based baby nutrition for this generation and the future ones to come.”

“I am thrilled to be partnering with Else Nutrition. As many of you know, my family primarily eats a dairy-free, plant-based diet. I nurse my babies and am always looking for a plant-based toddler formula to transition to once they are weaned. There hasn’t been anything suitable except soy until now. Else is complete, whole Nutrition and my toddler Romeo genuinely loves it. It’s really the alternative that I had been looking for, and I believe that so many other parents like myself have been longing for it as well,” said Mrs. Hilaria Baldwin.

Most recently, Else made its debut on national U.S. television. Baldwin appeared on E!’s popular midday show, Daily Popwhere she explained why Else is her choice for her toddler, Romeo. Else Nutrition’s Plant-Based Complete Nutrition for Toddlers & Babies (12+ mo.) is available for order on Else’s e-store at elsenutrition.com.

About Else Nutrition Holdings Inc.

Else Nutrition GH Ltd. is an Israel-based food and nutrition company focused on developing innovative, clean and plant-based food and nutrition products for infants, toddlers, children, and adults. Its revolutionary, plant-based, non-soy, formula is a clean-ingredient alternative to dairy-based formula. Else Nutrition (formerly INDI) won the “2017 Best Health and Diet Solutions” award at the Global Food Innovation Summit in Milan. The holding company, Else Nutrition Holdings Inc, is a publicly traded company, listed as TSX Venture Exchange under the trading symbol BABY and is quoted on the US OTC Markets QB board under the trading symbol BABYF and on the Frankfurt Exchange under the symbol 0YL. Else’s Executives includes leaders hailing from leading infant nutrition companies. Many of Else advisory board members had past executive roles in companies such as Mead Johnson, Abbott Nutrition, Plum Organics and leading infant nutrition Societies, and some of them currently serve in different roles in leading medical centers and academic institutes such as Boston Children’s Hospital, Pediatrics at Harvard Medical School, USA, Tel Aviv University, Schneider Children’s Medical Center of Israel, Rambam Medical Center and Technion, Israel and University Hospital Brussels, Belgium.

About Hilaria Baldwin

Hilaria Baldwin (@hilariabaldwin) is the Co-Host of Mom Brain, Apple’s #1 parenting podcast; the author of The Living Clearly Method: 5 Principles for a Fit Body, Healthy Mind & Joyful Life (Rodale; December 2016); and Co-Founder of Yoga Vida in NYC. She is also a monthly contributor to TODAY.com’s One Small Thing platform and to People’s People Parents Squad. Hilaria lives in NYC with her husband Alec and their four children, Carmen Gabriella, Rafael Thomas, Leonardo Angel and Romeo Alejandro David, and they’re currently expecting their fifth child.

For more information, visit: elsenutrition.com or @elsenutrition on Facebook and Instagram.

For additional information, contact:

Ms. Hamutal Yitzhak, CEO, Co-Founder & Director
ELSE Nutrition Holdings Inc.
E: [email protected]
P: +972(0)3-6445095

Mr. Sokhie Puar, Director
ELSE Nutrition Holdings Inc.
E: [email protected]
P: 604-603-7787

TSX Venture Exchange

Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Caution Regarding Forward-Looking Statements

This press release contains statements that may constitute “forward-looking statements” within the meaning of applicable securities legislation. Forward-looking statements are typically identified by words such as “will” or similar expressions. Forward-looking statements in this press release include statements with respect to the Company’s anticipated partnership with Mrs. Baldwin. Such forward-looking statements reflect current estimates, beliefs and assumptions, which are based on management’s perception of current conditions and expected future developments, as well as other factors management believes are appropriate in the circumstances. No assurance can be given that the foregoing will prove to be correct. Forward-looking statements made in this press release assume, among others Forward-looking statements made in this press release assume, among others, the successful partnership between the Company and Mrs. Baldwin. Actual results may differ from the estimates, beliefs and assumptions expressed or implied in the forward-looking statements. Readers are cautioned not to place undue reliance on any forward-looking statements, which reflect management’s expectations only as of the date of this press release. The Company disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

SOURCE: Else Nutrition Holdings

ImagineAR $IP.ca $IPNFF Signs Five Year $250,000 USD Licensing Agreement with WaV Sports & Entertainment $SEV.ca $VST.ca $YDX.ca $NTAR.ca

Posted by AGORACOM-JC at 7:12 AM on Wednesday, September 9th, 2020
http://www.smallcapepicenter.com/imagine%20ar%20squre.jpg
  • Contract Revenue is $250,000 USD Plus 5 Year Joint Partnership Program Revenue Fees
  • Licensing agreement to provide its Augmented Reality Platform to WaV Sports & Entertainment for the launch of their new proprietary line of global sports engagement products
  • In addition to the five-year licensing fee, the agreement also provides for joint revenue sharing fees over the term which can significantly increase the annual revenue for ImagineAR

VANCOUVER, BC and ERIE, Pa., Sept. 9, 2020 – Imagine AR Inc. (CSE: IP) (OTCQB: IPNFF) (“ImagineAR” or “Company”) is excited to announce the signing of a five year $250,000USD licensing agreement to provide its Augmented Reality Platform to WaV Sports & Entertainment for the launch of their new proprietary line of global sports engagement products. In addition to the five-year licensing fee, the agreement also provides for joint revenue sharing fees over the term which can significantly increase the annual revenue for ImagineAR.

Brian Klaasmeyer, Co-Founder & Managing Partner of WaV Sports & Entertainment stated “Our partnership with ImagineARTM is going to address the new paradigm required today in professional sports for fan engagement and activation.  The ImagineAR augmented reality platform is truly a gamechanger for sports organizations and athletes to deliver in-home mobile phone engagement and drive consistent recurring monthly revenue for them. We are extremely optimistic that with our experienced executive team, we will generate significant revenue for our clients for years.”

Dean Dalton, Co-Found & Managing Partner of WaV Sports & Entertainment, and former NFL Minnesota Vikings Coach added “We have been analyzing new technologies and platforms for revolutionizing sports and fan engagement. Augmented Reality has been one of our keystone requirements and the ImagineAR platform is years ahead of every other company today.” 

Alen Paul Silverrstieen, CEO of ImagineAR, stated “Our new advisor, Gus Frerotte, introduced the founders of WaV Sports and Entertainment to ImagineAR as he realized the potential of a partnership for both organizations.  We believe the WaV Sports fan engagement business model and current relationships are going to be a catalyst for driving significant revenue for ImagineAR in 2020 and for the duration of the five-year agreement.” 

This News Release is available on the company’s CEO Verified Discussion Forum, a moderated social media platform that enables civilized discussion and Q&A between Management and Shareholders.

ABOUT WaV Sports & Entertainment

WaV Sports & WaV Sports & Entertainment is a global sports marketing firm that specializes in sports property representation, brand side representation, and the management and production of unique sporting and entertainment events.  WaV exclusively represents the NFL Alumni Academy and various other NFL Alumni projects such as their youth educational programming known as Pro Day Experience.  WaV Sports & Entertainment has partnered with ImagineAR to expand their reach into the world of sports. Additional information on the Company can be found at www.WaVsports.com

About ImagineAR

ImagineAR Inc. (CSE: IP) (OTC: IPNFF) is an augmented reality (AR) platform, ImagineAR.com, that enables sports organizations and businesses of any size to create and implement their own AR campaigns with no programming or technology experience. Every organization, from professional sports franchises to small retailers, can develop interactive AR campaigns that blend the real and digital worlds. Customers simply point their mobile device at logos, signs, buildings, products, landmarks and more to instantly engage videos, information, advertisements, coupons, 3D holograms and any interactive content all hosted in the cloud and managed using a menu-driven portal. Integrated real-time analytics means that all customer interaction is tracked and measured in real-time. The AR Enterprise platform supports both IOS and Android mobile devices and upcoming wearable technologies.

For more information or to explore working with Imagination Park, please email [email protected], or visit www.imagineAR.com.

All trademarks of the property of respective owners.

ON BEHALF OF THE BOARD

Alen Paul Silverrstieen
President & CEO

(818) 850-2490
https://twitter.com/IPtechAR
https://www.facebook.com/imaginationparktechnologies
https://www.instagram.com/iptechar
https://www.linkedin.com/company/imagination-park-technologies-inc

We encourage you to do your own due diligence and ask your broker if Imagination Park Entertainment Inc. (cse: IP) is suitable for your particular investment portfolio*.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this press release. This press release may include ‘forward-looking information’ within the meaning of Canadian securities legislation, concerning the business of the Company. The forward looking information is based on certain key expectations and assumptions made by Imagination Park’s management. Although ImagineAR believes that the expectations and assumptions on which such forward- looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because ImagineAR can give no assurance that it will prove to be correct. These forward-looking statements are made as of the date of this press release, and ImagineAR disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

VIDEO – PyroGenesis $PYR.ca Receives $11.5M Contract For 2 Aircraft Carriers … But That May Not Be Their Biggest News $RTN $NOC $UTX $DDD.ca $SSYS $PRLB

Posted by AGORACOM-JC at 6:27 PM on Tuesday, September 8th, 2020

The most expensive real estate in the world measured by square foot is a US aircraft carrier.  If that wasn’t enough, it is also amongst the hardest places in the world to get your technology approved for use.

PyroGenesis has already sold two (2) plasma torch based systems to the US Navy for installation on two aircraft carriers … and now it has sold two more systems for 2 more US aircraft carriers to the tune of $11.5M.

The news is cause for celebration by both the Company and its shareholders, not just for the associated dollar value but for the additional reputational gains made by PYR as a result of a massive repeat order to the US Government.  There isn’t a small cap company in the world that wouldn’t be popping champagne bottles tonight.

Can you feel the BUT coming?  OK, here it is  …. But this US aircraft carrier news may not be the biggest news of the WEEK for PyroGenesis, let alone the year because just a few days earlier it announced the following:

PyroGenesis Announces Completion and Acceptance of Modelling Contract with Iron Ore Pelletization Client A; Receives Draft Contract for Equipment Purchase

How big could this development be?  In a press release earlier this year PYR stated the following:

The Client has over 10 plants, each requiring approx. 50 torches.Each torch will generate up to $3M of revenue to PyroGenesis. 

In case your calculator isn’t working, that’s 50 x 10 X $3,000,0000 = $1.5 BILLION.  However, we would be remiss if we didn’t insert this quote from PYR CEO Peter Pascali who stated:

“I must caution that although all parties are confident of the outcome, and the remaining details are minor, there is no guarantee that the Contract will, at the end of the day, be signed, until it is. We have no definite visibility on how long this will take but we are clearly in the final stages.”

If you are just discovering PyroGenesis (PYR:TSXV) then grab your favourite drink and watch this powerful video …. or listen in via podcast when you want to tune out the world and learn about an incredible company.

Please be sure to share this interview with your networks. 

July #Cannabis Sales Surge in 5 Western States – SPONSOR: Hollister Biosciences $HOLL.ca $WEED.ca $CGC $ACB $APHA $CRON.ca $OGI.ca $FAF.ca

Posted by AGORACOM-JC at 5:08 PM on Tuesday, September 8th, 2020

SPONSOR: Hollister Biosciences Inc. (HOLL:CSE) A vertically integrated Cannabis company with products in 230 California dispensaries, over 80 dispensaries throughout Arizona, joint ventures, licensing agreements and partnerships with Global brands. Revenue generated for the three-month period ended June 30th, 2020 was USD $8.47 million. Learn More

July Cannabis Sales Surge in 5 Western States

  • In July 2020, cannabis sales for state licensed retailers and delivery services reached $334.4 million, growing 15 percent from the trailing month and 26 percent compared to July 2019.
  • Year to date, sales in California have reached $1.9 billion, a 14 percent increase compared to the same period in 2019.
A Detailed Look at Cannabis Sales in California, Oregon, Arizona, Colorado and Nevada

Data provided by BDSA indicates that cannabis sales continued their robust expansion in 5 Western states. During July, the eleventh month after the onset of the vaping crisis and the fifth month of the pandemic impacting the market, sales across the five markets totaled $842.8 million, up 12% from June, which sequential increases of 2% in May and 14% in April. March had spiked to $666.0 million from $579.9 million in February as customers purchased cannabis ahead of store closures and concerns about limitations on access, so clearly cannabis sales are back on track. With the near-term effects of the pandemic now behind us, it’s clear that cannabis demand is surging, even in relatively mature markets, like Oregon and Colorado. Nevada continued to recover as tourism slowly returns, with sales growing 23%. California stood out with 15% sequential growth, while Colorado expanded 13%. Oregon sales climbed 6% and Arizona by 3%, but both of these states had meteoric growth from a year ago. July had one more day than June, which has the effect of adding 3% roughly.

Overall sales growth from a year ago among the five Western markets ranged from 26% in California to as high as 54% in Arizona. Nevada has been impacted by the tourist slowdown but still grew 37% from a year ago. Oregon continued its strong growth, rising 44%, while Colorado grew 35%. Concentrates represented 22-37% of sales by market, below the 26-38% share of sales last August before the vaping crisis hit.

Here is a closer look at each market, as detailed by BDSA:

Arizona

In July 2020, cannabis sales in Arizona’s medical dispensaries reached $94.2 million, growing three percent from June and over 54 percent compared to the previous July. Year-to-date through July, sales have reached $589.2 million, increasing by $194.5 million and 49 percent compared to the same period last year.

Flower sales accounted for nearly 48 percent of overall revenue for the month with $44.8 million in sales, growing one percent from June. Pre-rolled Joints, which are tracked as a separate category, accounted for just under four percent of revenue with $3.5 million in sales. Compared to the previous July, Flower sales increased by 52 percent and Pre-rolled Joints increased by 83 percent.

Concentrate sales accounted for about 37 percent of overall revenues with sales totaling $34.6 million in July, increasing six percent from the trailing month. Vape products, the largest segment of the Concentrates category, generated $21.8 million in sales, accounting for 63 percent of the Arizona Concentrates market and over 23 percent of sales across all categories. Compared to July 2019, sales of Dabbable Concentrates grew by 92 percent, while Vape sales grew by 46 percent.

The Ingestibles category accounted for nearly 11 percent of sales in July with $10 million in revenue for the month. Compared to July 2019 and June 2020, sales in the category grew by 47 percent and by four percent, respectively. In July, the $9.3 million in sales from Edibles generated nearly 93 percent of Ingestibles sales overall, while Sublinguals made up the remaining seven percent. Compared to the previous July, Edibles sales increased by 59 percent and Sublingual sales decreased by 30 percent.

California

BDSA sales reporting for the month of July reflects the state market of 699 licensed dispensary locations and 306 delivery operators.

In July 2020, cannabis sales for state licensed retailers and delivery services reached $334.4 million, growing 15 percent from the trailing month and 26 percent compared to July 2019. Year to date, sales in California have reached $1.9 billion, a 14 percent increase compared to the same period in 2019.

Sales from Flower generated $136.2 million in July 2020, accounting for nearly 41 percent of overall revenues. Compared to the trailing month and July 2019, Flower sales grew by 17 percent and 53 percent, respectively. Pre-rolled Joints, which are tracked as a separate category, accounted for nearly 11 percent of overall July revenues, with $35.6 million in sales.

Concentrates were the second-largest revenue category in July 2020, reaching $101 million in sales and accounting for over 30 percent of total revenue. Compared to the trailing month and July 2019, sales increased by 13 percent and by four percent, respectively. The $76 million in Vape sales accounted for over 75 percent of the Concentrates category and 23 percent of the month’s overall sales revenue.

In July 2020, Ingestibles generated $50.8 million in sales, increasing by 11 percent from the trailing month. Compared to July 2019, sales of Ingestibles grew by nearly 21 percent. Edibles contributed 86 percent of Ingestibles revenue, while Sublinguals made up the remaining 14 percent. Compared to July 2019, the Edibles and Sublinguals categories grew by 32 percent and declined by 22 percent, respectively.

Colorado

July 2020 was another milestone for the Colorado cannabis market. Sales in Colorado’s adult-use and medical dispensaries reached a combined $226.8 million, growing 13 percent from June. Compared to the previous July, sales increased by nearly 35 percent. Adult-use sales grew by 33 percent from July 2019 while medical sales grew by 41 percent. Year-to-date through July, combined channel sales have reached over $1.2 billion, increasing 22 percent from the same period last year.

In July, Flower sales accounted for over 47 percent of total monthly revenues, totaling at $107.2 million. Flower sales increased nearly 11 percent from the trailing month and grew 56 percent from the previous July. Year-to-date sales have increased by 40 percent in the category over the same period last year. Pre-rolled Joints, which are tracked separately from Flower, generated $13.2 million in sales for July 2020, growing 31 percent from July 2019 and increasing 17 percent from the trailing month.

The $66.5 million in Concentrate sales during July 2020 represented an 18 percent increase from the previous year and 15 percent growth from the trailing month. The category accounted for over 29 percent of revenue for the month. Vape products, the largest segment within the Concentrates category, reached $32.9 million in July sales, increasing 19 percent compared to June and four percent from the previous July, respectively. The Vape category accounted almost 50 percent of Concentrates’ revenue and 15 percent of overall sales for the month.

In July 2020, sales from Ingestibles generated $34.7 million, a 27 percent increase from July 2019. Compared to the trailing month, sales in the category grew by 17 percent. Edibles generated $32.7 million in monthly sales revenue, contributing over 94 percent to category sales and 14 percent of total revenue for the month. Sublinguals made up the remaining six percent of Ingestibles sales, totaling $1.9 million for the month.

Nevada

In July, Nevada dispensaries generated $82 million in sales. Compared to July of 2019, sales grew by 37 percent and by nearly 23 percent compared to the trailing month. Year-to-date through July, sales have reached $421.9 million, growing by six percent compared to the same period last year.

Flower sales accounted for nearly 54 percent of overall July 2020 sales. Sales in the category reached $44.1 million for the month, growing 27 percent from June. Pre-rolled Joints, tracked separately from Flower, accounted for nearly 11 percent of July sales, with $8.8 million in revenue. Compared to July 2019, Flower and Pre-rolled Joints sales have increased by 75 percent and by two percent, respectively.

Concentrate sales in July reached $18.3 million, accounting for more than 22 percent of overall revenue for the month. Compared to the trailing month as well as to the previous July, category sales increased by 17 percent. Vape products, the largest segment in the Concentrates category, generated $13.3 million for the month, contributing nearly 73 percent to Concentrates revenue and over 16 percent to total monthly sales.

Sales in the Ingestibles category accounted for 11 percent of all revenues, totaling $9.1 million in July sales and growing by about seven percent from the previous year. Compared to June, category sales grew by 17 percent. Edibles made up 90 percent of the Ingestibles category, reaching $8.2 million in July revenue, and Sublingual sales contributed the remaining ten percent.

Oregon

In July 2020, cannabis sales in Oregon’s medical and adult-use dispensaries reached a combined $106 million. Compared to the trailing month, sales in the Oregon market grew by about six percent, while compared to July 2019, sales grew by 45 percent overall. Year-to-date sales in Oregon have reached $620.3 million, growing by 39 percent compared to the same period in 2019.

Sales of Flower generated $50.3 million in July 2020, accounting for 47 percent of overall revenues. Compared to the trailing month, Flower sales grew by four percent, and compared to July 2019, sales increased by 65 percent. Pre-rolled Joints, which are tracked as a separate category, accounted for nine percent of overall revenues with $9.8 million in sales.

Concentrates generated $27.7 million in July sales. Compared to the trailing month and July 2019, sales in the category increased five percent and just over 25 percent, respectively. Vape products, the largest segment in the Concentrates category, generated $15 million in July, contributing over 54 percent of Concentrates sales and more than 14 percent of total monthly revenue.

In July 2020, Ingestibles generated over $14.6 million in sales, a nine percent increase from the previous month and nearly 25 percent compared to July 2019. Edibles, which made up 83 percent of the Ingestibles category and more than 11 percent of overall monthly sales, generated $12 million in July 2020.

For readers looking for a deeper look at cannabis markets across these five states and more, including segmentation by additional product categories, brand and item detail, longer history, and segmentation by product attributes, learn how the BDSA GreenEdge Platform can provide you with unlimited access to the most accurate and actionable data and analysis.

Source: https://www.newcannabisventures.com/july-cannabis-sales-surge-in-5-western-states/

PyroGenesis $PYR.ca Signs $11.5MM Contract for US Navy’s Two Ship Build $RTN $NOC $UTX $DDD.ca $SSYS $PRLB

Posted by AGORACOM-JC at 3:09 PM on Friday, September 4th, 2020
  • Signed an $11.5MM contract to provide PyroGenesis’ waste destruction systems
  • Contract is for two Systems, one for each ship in the US Navy’s two-ship build
  • Systems are expected to be built within the next 18 months, and are to be installed on the next Gerald R. Ford-class US aircraft carriers; the USS Enterprise (CVN-80) and the USS Doris Miller (CVN-81).
  • Includes a first payment of approx. $4.8MM
  • With this additional Contract in hand, the resulting backlog is expected to be approx. $40MM

MONTREAL, Sept. 04, 2020 — PyroGenesis Canada Inc. (http://pyrogenesis.com) (TSX-V: PYR) (OTCQB: PYRNF) (FRA: 8PY), a high-tech company, (the “Company”, the “Corporation” or “PyroGenesis”) that designs, develops, manufactures and commercializes plasma atomized metal powder, plasma waste-to-energy systems and plasma torch products, is pleased to announce that, further to its press release dated July 9th, 2020, it has signed an $11.5MM contract (the “Contract”) to provide PyroGenesis’ waste destruction systems (the “Systems”). This Contract is for two Systems, one for each ship in the US Navy’s two-ship build.

This Contract includes a first payment (“Down Payment”) of approx. $4.8MM. This project should be completed within 18 months. With this additional Contract in hand, the resulting backlog is expected to be approx. $40MM.

The Systems are expected to be built within the next 18 months, and are to be installed on the next Gerald R. Ford-class US aircraft carriers; the USS Enterprise (CVN-80) and the USS Doris Miller (CVN-81).  

“It is indeed an honor to supply our high-tech products to such a prestigious client as the US Navy. It speaks to our credibility as an innovator with a proven capability of delivering proprietary plasma processes to high value niche markets. Furthermore, it is also a testimony to the fact that PyroGenesis continues to develop commercial cutting-edge applications,” said P. Peter Pascali, President and CEO of PyroGenesis. “This backlog is quite significant particularly when taken in the context of the Company’s previous revenues (2019: $4.8MM, 2018: $5.0MM), and we look forward to adding to this in the very near future.”

About PyroGenesis Canada Inc.

PyroGenesis Canada Inc., a high-tech company, is the world leader in the design, development, manufacture and commercialization of advanced plasma processes and products. We provide engineering and manufacturing expertise, cutting-edge contract research, as well as turnkey process equipment packages to the defense, metallurgical, mining, advanced materials (including 3D printing), oil & gas, and environmental industries. With a team of experienced engineers, scientists and technicians working out of our Montreal office and our 3,800 m2 manufacturing facility, PyroGenesis maintains its competitive advantage by remaining at the forefront of technology development and commercialization. Our core competencies allow PyroGenesis to lead the way in providing innovative plasma torches, plasma waste processes, high-temperature metallurgical processes, and engineering services to the global marketplace. Our operations are ISO 9001:2015 and AS9100D certified, and have been since 1997. PyroGenesis is a publicly-traded Canadian Corporation on the TSX Venture Exchange (Ticker Symbol: PYR) and on the OTCQB Marketplace. For more information, please visit www.pyrogenesis.com.

This press release contains certain forward-looking statements, including, without limitation, statements containing the words “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “in the process” and other similar expressions which constitute “forward- looking information” within the meaning of applicable securities laws. Forward-looking statements reflect the Corporation’s current expectation and assumptions and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, our expectations regarding the acceptance of our products by the market, our strategy to develop new products and enhance the capabilities of existing products, our strategy with respect to research and development, the impact of competitive products and pricing, new product development, and uncertainties related to the regulatory approval process. Such statements reflect the current views of the Corporation with respect to future events and are subject to certain risks and uncertainties and other risks detailed from time-to-time in the Corporation’s ongoing filings with the securities regulatory authorities, which filings can be found at www.sedar.com, or at www.otcmarkets.com. Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. The Corporation undertakes no obligation to publicly update or revise any forward- looking statements either as a result of new information, future events or otherwise, except as required by applicable securities laws. Neither the TSX Venture Exchange, its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) nor the OTCQB accepts responsibility for the adequacy or accuracy of this press release.

SOURCE PyroGenesis Canada Inc.
For further information please contact:
Rodayna Kafal, Vice President Investors Relations and Strategic Business Development,
Phone: (514) 937-0002, E-mail: [email protected]
www.pyrogenesis.com

PyroGenesis $PYR.ca Signs $11.5MM Contract for US Navy’s Two Ship Build $RTN $NOC $UTX $DDD.ca $SSYS $PRLB

Posted by AGORACOM-JC at 2:42 PM on Friday, September 4th, 2020
  • Signed an $11.5MM contract to provide PyroGenesis’ waste destruction systems
  • Contract is for two Systems, one for each ship in the US Navy’s two-ship build
  • Systems are expected to be built within the next 18 months, and are to be installed on the next Gerald R. Ford-class US aircraft carriers; the USS Enterprise (CVN-80) and the USS Doris Miller (CVN-81).
  • Includes a first payment of approx. $4.8MM
  • With this additional Contract in hand, the resulting backlog is expected to be approx. $40MM.

MONTREAL, Sept. 04, 2020 — PyroGenesis Canada Inc. (http://pyrogenesis.com) (TSX-V: PYR) (OTCQB: PYRNF) (FRA: 8PY), a high-tech company, (the “Company”, the “Corporation” or “PyroGenesis”) that designs, develops, manufactures and commercializes plasma atomized metal powder, plasma waste-to-energy systems and plasma torch products, is pleased to announce that, further to its press release dated July 9th, 2020, it has signed an $11.5MM contract (the “Contract”) to provide PyroGenesis’ waste destruction systems (the “Systems”). This Contract is for two Systems, one for each ship in the US Navy’s two-ship build.

This Contract includes a first payment (“Down Payment”) of approx. $4.8MM. This project should be completed within 18 months. With this additional Contract in hand, the resulting backlog is expected to be approx. $40MM.

The Systems are expected to be built within the next 18 months, and are to be installed on the next Gerald R. Ford-class US aircraft carriers; the USS Enterprise (CVN-80) and the USS Doris Miller (CVN-81).  

“It is indeed an honor to supply our high-tech products to such a prestigious client as the US Navy. It speaks to our credibility as an innovator with a proven capability of delivering proprietary plasma processes to high value niche markets. Furthermore, it is also a testimony to the fact that PyroGenesis continues to develop commercial cutting-edge applications,” said P. Peter Pascali, President and CEO of PyroGenesis. “This backlog is quite significant particularly when taken in the context of the Company’s previous revenues (2019: $4.8MM, 2018: $5.0MM), and we look forward to adding to this in the very near future.”

About PyroGenesis Canada Inc.

PyroGenesis Canada Inc., a high-tech company, is the world leader in the design, development, manufacture and commercialization of advanced plasma processes and products. We provide engineering and manufacturing expertise, cutting-edge contract research, as well as turnkey process equipment packages to the defense, metallurgical, mining, advanced materials (including 3D printing), oil & gas, and environmental industries. With a team of experienced engineers, scientists and technicians working out of our Montreal office and our 3,800 m2 manufacturing facility, PyroGenesis maintains its competitive advantage by remaining at the forefront of technology development and commercialization. Our core competencies allow PyroGenesis to lead the way in providing innovative plasma torches, plasma waste processes, high-temperature metallurgical processes, and engineering services to the global marketplace. Our operations are ISO 9001:2015 and AS9100D certified, and have been since 1997. PyroGenesis is a publicly-traded Canadian Corporation on the TSX Venture Exchange (Ticker Symbol: PYR) and on the OTCQB Marketplace. For more information, please visit www.pyrogenesis.com.

This press release contains certain forward-looking statements, including, without limitation, statements containing the words “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “in the process” and other similar expressions which constitute “forward- looking information” within the meaning of applicable securities laws. Forward-looking statements reflect the Corporation’s current expectation and assumptions and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, our expectations regarding the acceptance of our products by the market, our strategy to develop new products and enhance the capabilities of existing products, our strategy with respect to research and development, the impact of competitive products and pricing, new product development, and uncertainties related to the regulatory approval process. Such statements reflect the current views of the Corporation with respect to future events and are subject to certain risks and uncertainties and other risks detailed from time-to-time in the Corporation’s ongoing filings with the securities regulatory authorities, which filings can be found at www.sedar.com, or at www.otcmarkets.com. Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. The Corporation undertakes no obligation to publicly update or revise any forward- looking statements either as a result of new information, future events or otherwise, except as required by applicable securities laws. Neither the TSX Venture Exchange, its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) nor the OTCQB accepts responsibility for the adequacy or accuracy of this press release.

SOURCE PyroGenesis Canada Inc.
For further information please contact:
Rodayna Kafal, Vice President Investors Relations and Strategic Business Development,
Phone: (514) 937-0002, E-mail: [email protected]
www.pyrogenesis.com

VIDEO: Watch Out, #AlecBaldwin, Hilaria’s got a new love :-) Else Nutrition $BABY.ca $KMB $BMY $ABT $WYE

Posted by AGORACOM-JC at 11:04 AM on Wednesday, September 2nd, 2020
http://blog.agoracom.com/wp-content/uploads/2020/03/else-square-150x150.png

Hilaria Baldwin Chooses Else Nutrition on E! Daily Pop

https://youtu.be/UBiYSt9Jekg

“As many of you know, my family primarily eats a dairy-free, plant-based diet. I nurse my babies and am always looking for a plant-based toddler formula to transition to once they are weaned. There hasn’t been anything on the market except soy until now. This is why I’m so excited to share @elsenutrition with you – it’s the first clean-label, plant-based formula for toddlers. Romeo and I are making their Complete Nutrition Drink which helps support his growth and development during this key time. Else is organic and non-GMO. It’s FDA-compliant, dairy, soy, and hormone-free. There are no antibiotics, palm oil, or corn syrups that are traditionally found in infant and toddler formulas and milks, so your babies can get the nutrition nature intended! I highly recommend this amazing alternative, especially if you’re like me where you’ve been looking for something Else!”

VIDEO – Hollister $HOLL.ca Reports Record Q2 Revenues With $8.47M From 300+ Dispensaries In California and Arizona $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca

Posted by AGORACOM-JC at 6:28 PM on Tuesday, September 1st, 2020
https://prnewswire2-a.akamaihd.net/p/1893751/sp/189375100/thumbnail/entry_id/1_dd2snc3b/def_height/400/def_width/400/version/100011/type/1

Hollister Biosciences (HOLL:CSE). is a multi-state operator with multiple, high-quality products that are now carried in 230 of California’s 600 dispensaries, where it also claims California’s #1 hash infused pre-roll “HashBone” + another 80 Arizona dispensaries with some of the best concentrate in the State.  

But given the state of disappointment in the Cannabis industry over the last 15 months, none of that would mean anything without actual results shareholders and the industry could celebrate.  In that regard, Hollister does not disappoint with Q2 numbers coming in as follows:

  • RECORD REVENUE of $US 8.47M, compared to $200,000 last year and representing an increase of 4,170%
  • NET INCOME of $300,000, compared to a loss of $2.1M, representing a turnaround of $2.4M over last year 

There isn’t a small cap cannabis company that would not cheer for these results – if that was all they had.  These numbers are a company maker.   But Hollister is set to continue growing on several fronts, including a Direct To Consumer model and further big expansion in California.  

Watch this incredible interview with President Alex Somjen.   

Watch this interview or listen by Podcast on AppleGoogleSpotify or your favourite podcaster.

PyroGenesis $PYR.ca Announces Completion and Acceptance of Modelling Contract with Iron Ore Pelletization Client A; Receives Draft Contract for Equipment Purchase $RTN $NOC $UTX $DDD.ca $SSYS $PRLB

Posted by AGORACOM-JC at 3:13 PM on Tuesday, September 1st, 2020
  • Announced the completion and acceptance of its modeling contract with Client A which confirmed, amongst other things, that replacing fossil fuel burners with PyroGenesis’ proprietary plasma torches addresses the Client’s greenhouse gas reduction strategy/policy
  • PyroGenesis is also pleased to confirm receipt of a draft equipment purchase contract from Client A
  • Client’s name shall remain anonymous for competitive and confidential reasons

MONTREAL, Sept. 01, 2020 — PyroGenesis Canada Inc. (http://pyrogenesis.com) (TSX-V: PYR) (OTCQB: PYRNF) (FRA: 8PY), a high-tech company, (the “Company”, the “Corporation” or “PyroGenesis”) that designs, develops, manufactures and commercializes plasma atomized metal powder, plasma waste-to-energy systems and plasma torch systems, further to its press release dated July 2nd, 2020, is pleased to announce the completion and acceptance of its modeling contract with Client A (the “Client”) which confirmed, amongst other things, that replacing fossil fuel burners with PyroGenesis’ proprietary plasma torches addresses the Client’s greenhouse gas reduction strategy/policy. PyroGenesis is also pleased to confirm receipt of a draft equipment purchase contract (the “Contract”) from Client A. The Client’s name shall remain anonymous for competitive and confidential reasons.

The modeling contract, disclosed in previous press releases, successfully demonstrated the benefits of replacing fossil fuel burners with PyroGenesis’ proprietary plasma torches. More specifically, two of the most important benefits demonstrated were i) that replacing fossil fuel burners with plasma torches was a simple replacement, plug and play process, and ii) that PyroGenesis’ proprietary plasma torches significantly reduce greenhouse gas emissions which, as a result, could play a significant role in Client A’s greenhouse gas reduction strategy/policy.

The Company also confirms having received a Contract which essentially highlights the terms and conditions negotiated to date. Although the major terms and conditions contained therein have been agreed to in principle, there are still several elements that need further review.

“The fact that we have received this Contract, on the heels of a successful modelling contract, from a significant player in the industry, clearly demonstrates the impact that PyroGenesis’ proprietary plasma torches are having in iron ore pelletization greenhouse gas reduction strategies,” said Mr. Peter Pascali, CEO and President of PyroGenesis. “Of note, PyroGenesis has the patent with respect to using plasma torches in iron ore pelletization as described. I must caution that although all parties are confident of the outcome, and the remaining details are minor, there is no guarantee that the Contract will, at the end of the day, be signed, until it is. We have no definite visibility on how long this will take but we are clearly in the final stages. We are all very excited at the significant role PyroGenesis’ proprietary plasma torches could play in reducing greenhouse gases, economically, all to the benefit of our planet.”

Pelletization is the process in which iron ore is concentrated before shipment, thus significantly reducing the cost of transportation. In conventional technologies, the process heat is provided by fuel oil or natural gas burners (both environmentally damaging). The combustion, in the burners, of fossil fuels results in the production of greenhouse gases, mainly CO2. Plasma torches, by contrast, utilize renewable electricity and as such offer an environmentally attractive alternative to fossil fuel burners.

About PyroGenesis Canada Inc.

PyroGenesis Canada Inc., a high-tech company, is the world leader in the design, development, manufacture and commercialization of advanced plasma processes and products. We provide engineering and manufacturing expertise, as well as turnkey process equipment packages to the defense, metallurgical, mining, advanced materials (including 3D printing), oil & gas, and environmental industries. With a team of experienced engineers, scientists and technicians working out of our Montreal office and our 3,800 m2 manufacturing facility, PyroGenesis maintains its competitive advantage by remaining at the forefront of technology development and commercialization. Our core competencies allow PyroGenesis to lead the way in providing innovative plasma torches, plasma waste processes, high-temperature metallurgical processes, and engineering services to the global marketplace. Our operations are ISO 9001:2015 and AS9100D certified, and have been since 1997. PyroGenesis is a publicly-traded Canadian Corporation on the TSX Venture Exchange (Ticker Symbol: PYR) and on the OTCQB Marketplace. For more information, please visit www.pyrogenesis.com.

This press release contains certain forward-looking statements, including, without limitation, statements containing the words “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “in the process” and other similar expressions which constitute “forward- looking information” within the meaning of applicable securities laws. Forward-looking statements reflect the Corporation’s current expectation and assumptions and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, our expectations regarding the acceptance of our products by the market, our strategy to develop new products and enhance the capabilities of existing products, our strategy with respect to research and development, the impact of competitive products and pricing, new product development, and uncertainties related to the regulatory approval process. Such statements reflect the current views of the Corporation with respect to future events and are subject to certain risks and uncertainties and other risks detailed from time-to-time in the Corporation’s ongoing filings with the securities regulatory authorities, which filings can be found at www.sedar.com, or at www.otcmarkets.com. Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. The Corporation undertakes no obligation to publicly update or revise any forward- looking statements either as a result of new information, future events or otherwise, except as required by applicable securities laws. Neither the TSX Venture Exchange, its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) nor the OTCQB accepts responsibility for the adequacy or accuracy of this press release.

SOURCE PyroGenesis Canada Inc.

For further information please contact:
Rodayna Kafal, Vice President Investors Relations and Strategic Business Development
Phone: (514) 937-0002, E-mail: [email protected]

Empower Clinics $CBDT.ca Announces Acquisition of Medical Diagnostics Laboratory $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 7:06 AM on Tuesday, September 1st, 2020

Empower intends to acquire Kai Medical Laboratory, a state-of-the-art diagnostics laboratory located in the medical district of Dallas, TX to advance COVID-19 national testing programs

  • Entered into a non-binding term sheet to acquire the business of Kai Medical Laboratory, LLC, by way of a share or asset acquisition, subject to due diligence and customary closing conditions
  • Kai Medical Laboratory is a high-complexity CLIA and COLA accredited Laboratory that provides reliable and accurate testing solutions to hospitals, medical clinics, pharmacies, and employer groups
  • Kai Medical Laboratory offers a wide array of testing services ranging from hematology to hormone testing, endocrinology, toxicology, and immunology

VANCOUVER, BC / September 1, 2020 / EMPOWER CLINICS INC. (CSE:CBDT) (Frankfurt:8EC) (OTCQB:EPWCF) (“Empower” or the “Company“) today announces it has entered into a non-binding term sheet to acquire the business of Kai Medical Laboratory, LLC (“Kai Medical Laboratory“), by way of a share or asset acquisition, subject to due diligence and customary closing conditions.

Kai Medical Laboratory is a high-complexity CLIA and COLA accredited Laboratory that provides reliable and accurate testing solutions to hospitals, medical clinics, pharmacies, and employer groups. Kai Medical Laboratory offers a wide array of testing services ranging from hematology to hormone testing, endocrinology, toxicology, and immunology. These tests are done under the supervision of its well-qualified and highly experienced scientists, medical professionals, and pharmacists. https://www.kaimedicallaboratory.com

Kai Medical Laboratory has taken an active role in COVID-19 testing, battling the pandemic through RT-PCR testing and serology testing. While the RT-PCR test identifies if a patient has an active virus, the serology or antibody test detects if a patient has previously been exposed to the virus. Both of these test results are vital to managing outbreaks and the potential spread of coronavirus.

To further assist with COVID-19 testing, Kai Medical Laboratory has also developed two key programs in Texas and Arizona. The first program is a direct-to-consumer program that leverages the ability of various healthcare providers to order and administer both the RT-PCR test and the Antibody test. This increases the ability of the general population to be tested, in certain circumstances. The second is an Employer COVID-19 Compliance Program (ECCP) for business owners and employer groups to enable them to test and monitor their employees.

Texas program https://www.testtexasnow.com

Arizona program https://www.covidtest2u.com

Currently the lab has the capacity to complete in excess of 2,000 RT-PCR tests in one eight-hour shift by utilizing its Thermo Fisher QuantStudio 12k Flex testing machine. The lab also utilizes a Roche Cobas 6000 for COVID-19 Antibody testing, ensuring that Kai Medical Laboratory has the capability and capacity to serve a broad range of clients and test methods.

“Adding Kai Medical Laboratory to the Empower Clinics family enables us to dramatically expand COVID-19 testing capability and deliver phase four of our national rollout plan” said Steven McAuley, Empower’s Chairman & CEO. “Kai Medical has a newly built high-complexity lab offering a wide array of testing services, that together we will leverage to serve the massive demand for national COVID testing in the U.S. Further, as flu season arrives and a potential second-wave of COVID takes hold, the technical infrastructure of Kai Medical allows Empower to capture testing demand and the additional growth revenues associated with it.”

The driving force behind Kai Medical Laboratory’s remarkable growth and success is Yoshi Tyler. Yoshi has a passion for being an entrepreneur, and overtime, she found her true calling in healthcare. Driven by this interest, she pursued her career in the healthcare industry for more than two decades. She helmed leadership positions at a Fortune 500 pharmaceutical company for over thirteen years. These leadership experiences provided her with in-depth knowledge and industry insights that helped her to lead Kai Medical Laboratory towards growth.

The Kai Medical Laboratory team includes key roles including Principal Scientist, Director of Operations, Molecular Scientist, Quality Assurance, Lab Director and other critical roles.

“Kai Medical Laboratory is inspired by science and built on integrity. Our mission is to change healthcare through science & innovative quality care by providing value-added services, accuracy, and consistency. Our unwavering commitment to quality compliance and scientific innovation elevates Kai Medical Laboratory to a new standard in healthcare,” says Yoshi Tyler, the owner, and CEO of the company.

The proposed acquisition includes an 8,000 sq. ft. medical laboratory including covered drive up testing center, with premium testing and laboratory equipment, cash and current assets with a value in excess of $1,750,000.00 USD and a corporate office, both located in the heart of the medical district in Dallas, TX. Under the proposed terms Empower will assume a $1,200,000.00 USD Small Business Administration (SBA) equipment loan, a $150,000.00 SBA Economic Injury Disaster Loan and short-term liabilities of up to $250,000.00 at closing. In addition, Empower will issue 1,000,000 Company stock options to the Vendors, subject to the terms and conditions as set out in the Company Stock Option Plan.

Market Leading Technology Kai Medical Laboratory utilizes state-of-the-art instrumentation, preeminent testing methodologies, and laboratory services enabling high-complexity accredited laboratory testing solutions, providing some of the following key instrument testing capabilities:

  • Thermo Fisher – QuantStudio 12K Flex
    • COVID-19 testing
    • Cannabis Testing
    • Clinical Genomics
  • Roche Cobas 6000
    • COVID-19 Antibody testing
    • Clinical Chemistry/Endocrinology
  • AB SCIEX 6500+ – Liquid Chromatography Mass Spectrometry
    • Clinical Chemistry/Endocrinology
    • Agriculture/Cannabis testing
  • AB SCIEX 4500 – Liquid Chromatography Mass Spectrometry
    • Urine Toxicology
    • Cannabis testing
  • SYSMEX XN-550
    • Hematology

USA COVID-19 Data as at August 31, 2020

TOTAL CASES: 5,972,356

TOTAL DEATHS: 182,622

CASES IN LAST 7 DAYS: 289,865

ARIZONA as at August 31, 2020

CONFIRMED CASES: 199,984

PROBABLE CASES: 1,713

TOTAL CASES: 201,661

CASES IN LAST 7 DAYS: 3,558

CASES/100K: 1,769

DEATHS/100K: 70

TEXAS as at August 31, 2020

TOTAL CASES: 610,354

CASES IN LAST 7 DAYS: 32,817

CASES/100K: 2,126

DEATHS/100K: 46

(CLIA) The Clinical Laboratory Improvement Amendments regulate laboratory testing and require clinical laboratories to be certified by the Center for Medicare and Medicaid Services (CMS) before they can accept human samples for diagnostic testing.

(COLA) is the premier clinical laboratory accreditation, education and consultation organization. An independent accreditor whose practical, educational standards have a positive and immediate impact on patient care. http://www.cola.org

The transaction is expected to be structured on a tax efficient basis, and otherwise in accordance with the requirements of requisite securities laws and the policies of the CSE. Empower has agreed to enter into employment agreements with Yoshi Tyler and Michael Haines, each having an initial term of two years.

Completion of the transaction will be subject to various conditions, including entry into a definitive agreement, completion of due diligence, and receipt of all required shareholder, manager, third party and regulatory approvals, including approval of the CSE. Closing of the transaction is expected to occur prior to October 15, 2020.

ABOUT EMPOWER

Empower is a vertically integrated health & wellness company with a network of corporate and franchised health & wellness clinics in the U.S. The Company is focused on helping patients improve and protect their health, through innovative physician recommended treatment options. The Company has launched Dosed Wellness Ltd. to connect its significant data, to the potential of the efficacy of alternative treatment options related to hemp-derived cannabidiol (CBD) therapies, psilocybin and other psychedelic plant-based treatment options. The Company provides COVID-19 testing services to consumers and businesses as part of a four-phased nationwide testing initiative.

ABOUT KAI MEDICAL LABORATORY

Our mission is to change healthcare through science & innovative quality care by providing value added services, accuracy, and consistency. Our unwavering commitment to quality compliance and scientific innovation elevates Kai Medical Laboratory to a new standard in patient care. Kai Medical Laboratory is located in the Dallas Medical District in close proximity to some of the largest healthcare groups in the U.S. including Parkland Hospital, UT Southwestern, Children’s Medical Center, Baylor Scott & White Health (Dallas), Tenet Healthcare (Dallas), CHRISTUS Healthcare (Dallas).

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Investors: Dustin Klein

Director
[email protected]
720-352-1398

Investors: Steven McAuley

CEO
[email protected]
604-789-2146

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release.Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include, but are not limited to, statements regarding: the expected benefits to the Company and its shareholders as a result of the proposed acquisition of Sun Valley; the proposed transaction terms; the expected number of clinics and patients following the closing; the future potential success of Sun Valley’s franchise model; the anticipated date of closing of the acquisition and the occurrence thereof; and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2019 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: that the Kai Medical Laboratory acquisition may not be completed on the terms expected or at all; that the Company’s products may not work as expected; that the Company may not be able to expand COVID-19 testing; that legislative changes may have an adverse affect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed transaction; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

SOURCE: Empower Clinics Inc.